Search Results - "HAMMOND, Sarah P"

American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy by Reddy, K. Rajender, Beavers, Kimberly L, Hammond, Sarah P, Lim, Joseph K, Falck-Ytter, Yngve T

Get full text

The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer by Ganatra, Sarju, Hammond, Sarah P., Nohria, Anju

Get full text

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel by Raje, Noopur, Anderson, Kenneth, Einsele, Hermann, Efebera, Yvonne, Gay, Francesca, Hammond, Sarah P., Lesokhin, Alexander M., Lonial, Sagar, Ludwig, Heinz, Moreau, Philippe, Patel, Krina, Ramasamy, Karthik, Mateos, Maria-Victoria

“…Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to…”
Get full text

Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation by Chen, Kaiwen, Cheng, Matthew P., Hammond, Sarah P., Einsele, Hermann, Marty, Francisco M.

“…Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of cytomegalovirus (CMV) reactivation and disease, which results in…”
Get full text

Molecular Methods To Improve Diagnosis and Identification of Mucormycosis by HAMMOND, Sarah P, BIALEK, Ralf, MILNER, Danny A, PETSCHNIGG, Eva M, BADEN, Lindsey R, MARTY, Francisco M

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies by Little, Jessica S, Weiss, Zoe F, Hammond, Sarah P

“…The use of targeted biologic therapies for hematological malignancies has greatly expanded in recent years. These agents act upon specific molecular pathways…”
Get full text

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease by Cornely, Oliver A, Robertson, Michael N, Haider, Shariq, Grigg, Andrew, Geddes, Michelle, Aoun, Mickael, Heinz, Werner J, Raad, Issam, Schanz, Urs, Meyer, Ralf G, Hammond, Sarah P, Mullane, Kathleen M, Ostermann, Helmut, Ullmann, Andrew J, Zimmerli, Stefan, Van Iersel, M L P S, Hepler, Deborah A, Waskin, Hetty, Kartsonis, Nicholas A, Maertens, Johan

“…A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as…”
Get full text

Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation by Cheng, Matthew P, Kusztos, Amanda E, Bold, Tyler D, Ho, Vincent T, Glotzbecker, Brett E, Hsieh, Candace, Baker, Meghan A, Baden, Lindsey R, Hammond, Sarah P, Marty, Francisco M

“…Abstract There were no cases of tuberculosis in a cohort of 2531 patients who underwent hematopoietic cell transplantation from 2010 to 2015 after 7323…”
Get full text

Isavuconazole Treatment of a Patient with Disseminated Mucormycosis by Peixoto, Driele, Gagne, Lisa S, Hammond, Sarah P, Gilmore, Erin T, Joyce, Amy C, Soiffer, Robert J, Marty, Francisco M

“…Classifications Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009 by HAMMOND, Sarah P, BADEN, Lindsey R, MARTY, Francisco M

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation by Prestes, Daniel P., Arbona, Esther, Nevett-Fernandez, Alexandra, Woolley, Ann E., Ho, Vincent T., Koo, Sophia, Baden, Lindsey R., Koreth, John, Hammond, Sarah P., Issa, Nicolas C., Marty, Francisco M.

“…Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that…”
Get full text

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors by Waks, Adrienne G., Tolaney, Sara M., Galar, Alicia, Arnaout, Amal, Porter, Julie B., Marty, Francisco M., Winer, Eric P., Hammond, Sarah P., Baden, Lindsey R.

“…Opportunistic infection with Pneumocystis jiroveci pneumonia (PCP) has not been recognized as a significant complication of early-stage breast cancer…”
Get full text

Respiratory Virus Detection in Immunocompromised Patients with FilmArray Respiratory Panel Compared to Conventional Methods by HAMMOND, Sarah P, GAGNE, Lisa S, STOCK, Shannon R, MARTY, Francisco M, GELMAN, Rebecca S, MARASCO, Wayne A, PORITZ, Mark A, BADEN, Lindsey R

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis by Chen, Kaiwen, Arbona‐Haddad, Esther, Cheng, Matthew P., McDonnell, Anne M., Gooptu, Mahasweta, Orejas, Jose L., Timblin, Kaitlyn, Silverman, Emily, Al‐Hamed, Rama, Soiffer, Robert J., Hammond, Sarah P., Marty, Francisco M.

“…Letermovir is approved for the prevention of cytomegalovirus (CMV) reactivation and clinical disease in patients undergoing allogeneic hematopoietic‐cell…”
Get full text

Infections in Composite Tissue Allograft Recipients by Hammond, Sarah P., MD

“…This article summarizes infectious complications in recipients of facial and hand composite tissue allotransplantation (CTA) and reviews infection prophylaxis…”
Get full text

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity by Gonzalez-Bocco, Isabel H, Beluch, Katherine, Cho, Alyssa, Lahoud, Chloe, Reyes, Fabiola A, Moshovitis, Dimitrios G, Unger-Mochrie, Gillian M, Wang, Wei, Hammond, Sarah P, Manne-Goehler, Jennifer, Koo, Sophia

“…Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20-40% of immunocompromised people fail to develop…”
Get full text

Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience by Stempel, Jessica M., Hammond, Sarah P., Sutton, Deanna A., Weiser, Linda M., Marty, Francisco M.

“…Invasive fusariosis is an aggressive fungal disease among immunocompromised patients. Mortality remains high in the voriconazole era. Combination therapy…”
Get full text

The Clinical Significance of Cytomegalovirus Viremia after Chimeric Antigen Receptor T-Cell Therapy by Hammond, Sarah P, Little, Jessica S

Get full text

Defining infection risk of bispecific antibodies for myeloma by Hammond, Sarah P.

Get full text

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies by Kampouri, Eleftheria, Little, Jessica S., Rejeski, Kai, Manuel, Oriol, Hammond, Sarah P., Hill, Joshua A.

“…Background Chimeric antigen receptor (CAR)‐T‐cell therapies have revolutionized the management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and…”
Get full text